Table 3 A review of recent studies focusing on MMR immunohistochemistry in ovarian clear cell carcinoma in chronological order
Study | Country | dMMR Rate | Sample | Pattern |
|---|---|---|---|---|
Bennett et al. | USA | 6% (6/109) | Whole section slides | MSH2/MSH6 (3), MLH1/PMS2 (1), MSH6 (1), PMS2 (1) |
Rambau et al. | Canada | 2.4% (4/164) | Tissue microarray | MSH2/MSH6 (3), MSH6 (1) |
Willis et al. | USA | 13% (3/23) | Whole section slides | MSH2/MSH6 (3) |
Stewart et al. | Australia | 6% (2/32) | Whole section slides | MSH2/MSH6 (2) |
Howitt et al. | USA | 10% (3/30) | Whole section slides | Not mentioned |
Xiao et al. | China | 4% (2/50) | Tissue microarray | MLH1/PMS2 (1), PMS2 low (1) |
Parra-Herran et al. | Canada | 2% (2/90) | Tissue microarray | MSH2/MSH6 (1), MSH6 (1) |
Fraune et al. | Germany | 0/23 | Tissue microarray | / |
Our study | China | 5.6% (6/108) | Whole section slides | MSH2/MSH6 (4), MLH1/PMS2 (2) |